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Abstract 
Review on the various t(14;19)(q32;q13), with data 
on clinics, and the genes involved. 
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Clinics and pathology 
Disease 
According to a search in Mitelman database "Cases 
Quick Searcher", 181 cases of t(14;19)(q32;q13) are 
available in the literature: 104 chronic lymphocytic 
leukemia cases (CLL), 30 acute B-cell 
lymphoblastic leukemia, 13 nodal marginal zone B-
cell lymphoma, 12 mature B-cell neoplasm not 
otherwise specified (NOS), 10 diffuse large B-cell 
lymphoma, 5 splenic marginal zone B-cell 
lymphoma, 2 follicular lymphoma, 1 bilineage 
leukemia, 1 Burkitt lymphoma, 1 chronic myeloid 
leukemia, 1 lymphoplasmacytic lymphoma, and 1 
mantle cell lymphoma.  
A t(14;19)(q32;q13) IGH/BCL3 has been found in 
chronic lymphocytic leukemia, mature B-cell 
neoplasm NOS, diffuse large B-cell lymphoma, 
bilineage leukemia, follicular lymphoma, Hodgkin 
disease, nodal marginal zone B-cell lymphoma, and 
splenic marginal zone B-cell lymphoma.  
A t(14;19)(q32;q13) IGH/CEBPA or CEBPG, but 
also other translocations with IGH fused to 
CCAAT/enhancer binding proteins (CEBPB 
(20q13), CEBPD (8p11), CEBPE (14q11)) has been 
found so far only in acute B-cell lymphoblastic 
leukemia.  
Other t(14;19)(q32;q13) with IGH involvement 
have been found in multiple myeloma (IGH/ERF, 
IGH/FOSB, IGH/PPP1R15A (Cleynen et al., 2017)) 
and diffuse large B-cell lymphoma (IGH/NECTIN2, 
IGH/SPIB (Lenz et al 2007; Otto et al., 2016)). 
Cytogenetics 
 t(14;19)(q32;q13) IGH/BCL3  
 t(14;19)(q32;q13) IGH/CEBPA or CEBPG 
 t(14;19)(q32;q13)IGH/ERF  
 t(14;19)(q32;q13) IGH/FOSB  
 t(14;19)(q32;q13) IGH/NECTIN2  
 t(14;19)(q32;q13) IGH/PPP1R15A  
 t(14;19)(q32;q13) IGH/SPIB  
Cytogenetics 
Cytogenetics morphological 
IGH partners in the t(14;19)(q32;q13) 
Gene Chrom. Band Starts-Ends (from pter) 
CEBPA 19q13.11 33,299,934 - 33,302,564 
CEBPG 19q13.11 33,373,669 - 33,382,686 
ERF 19q13.2 42,247,561 - 42,255,164 
BCL3 19q13.32 44,748,721 - 44,760,044 
NECTIN2 19q13.32 44,846,136 - 44,878,941 
FOSB 19q13.32 45,467,995 - 45,475,179 
PPP1R15A 19q13.33 48,872,392 - 48,876,062 
SPIB 19q13.33 50,418,938 - 50,431,052 
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Genes involved and 
proteins 
IGH (immunoglobulin heavy locus) 
Location 14q32.33 
BCL3 (BCL3 transcription 
coactivator) 
Location 19q13.32 
Starts at 44748721 and ends at 44760044 bp from 
pter. 
Protein 
454 amino acids (aa). BCL3 contains seven ankyrin 
repeats (aa 134-163, 171-200, 204-235, 241-270, 
275-304, 308-337, 338-367). BCL3 is a member of 
the I-kappaB family (NFKBIA (NFKB inhibitor 
alpha), NFKBIB (NFKB inhibitor beta) and others), 
whose proteins regulate the NF-kB family of 
transcription factors. BCL3 interacts with NFKB1 
and NFKB2 (NF-kappaB p50 and p52). NF-kB plays 
a major role in B-cell development. BCL3 is induced 
by LIF and plays a role in the maintenance of 
pluripotency. BCL3 stimulates cell-cycle 
progression in a breast cancer cell line. BCL3 
interacts with TRAF6. The ankyrin repeats of BCL3 
bind the RING domain of TRAF6. TRAF6 mediate 
a NF-kB signaling via BCL3 to promote 
osteoclastogenesis (Otsuka et al., 2018; Wang et al., 
2018) 
CEBPA (CCAAT/enhancer binding 
protein (C/EBP), alpha) 
Location 19q13.11 
Starts at 33299934 and ends at 33302564 bp from 
pter. 
Protein 
358 amino acids. CEBPA contains a bzip (aa 282-
345, with a basic motif (aa 286-313) and a leucine 
zipper (aa 317-345)). Transcription factor. Binds the 
consensus DNA sequence T[TG]NNGNAA[TG] as 
a homo or heterodimer. Key factor driving myeloid 
cell differentiation of hematopoietic stem cells and 
also driving differentiation of other cell lineages 
(Tian and Graf, 2014). 
CEBPG (CCAAT enhancer binding 
protein gamma) 
Location 19q13.11 
Starts at 33373669 and ends at 33382686 bp from 
pter. CEBPG is located only 71 kb distal of CEBPA. 
Protein 
150 amino acids. CEBPAG contains a bzip (aa 62-
125, with a basic motif (aa 66-93) and a leucine 
zipper (aa 97-118)).  
Transcription factor. CEBPB homodimers are 
cytostatic and promote cell cycle arrest and 
senescence. Conversely, CEBPB/CEBPG 
heterodimers display reduced transcriptional 
potential. However, CEBPG deletion did not alter 
hematopoietic stem and progenitor cell ability to 
commit to the myeloid lineage. ATF4/CEBPG 
heterodimer is an antioxidant regulator that controls 
redox homeostasis in normal and cancerous cells. 
CEBPG acts as a negative regulator of senescence 
and promotes proliferation of multiple cell types 
(Huggins et al., 2013; Huggins et al., 2015; 
Kardosova et al., 2018). 
ERF (ETS2 repressor factor) 
Location 19q13.2 
Starts at 42247561 and ends at 42255164 bp from 
pter. 
Protein 
548 amino acids. ERF contains an ETS domain (aa 
29-106), an ERK interaction domain (aa 294-385), 
and a repressor domain (aa 472-530). Member of the 
ETS family of transcription factors. ERF 
translocates to the nucleus, where it binds to 
enhancers of RAS targets, pluripotency and 
mitogenic factors. ERF may play a role in limiting 
mouse embryonic stem cells differentiation. Loss-of-
function ERF germline mutations are implicated in 
an autosomal form of craniosynostosis (Mayor-Ruiz 
et al., 2018). 
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FOSB (FosB proto-oncogene, AP-1 
transcription factor subunit) 
Location 19q13.32 
Starts at 45467995 and ends at 45475179 bp from 
pter.  
FOSB is also called AP-1 (which is confusing with 
the "AP-1 complex"). 
Protein 
338 amino acids. FOSB contains a bzip (aa 155-218, 
with a basic motif (aa 157-182) and a leucine zipper 
(aa 183-211)). Transcription factor, member of the 
AP-1 Transcription Factors family: AP-1 complex is 
a dimeric complex composed of members from the 
JUN, FOS (FOS, FOSB, FOSL1 and FOSL2 (FRA-
1 and FRA-2)), ATF, or MAF protein families. The 
sequence elements to which AP-1 transcription 
factors bind differ depending on the distinctive 
homo- or hetero-dimer combinations. FOS proteins 
bind the TRE sequence: TGACTCA. FOS proteins 
only form hetero-dimers (review in Garces de Los 
Fayos Alonso et al., 2018).  
ΔFosB, a splice variant of FOSB is induced by stress, 
antidepressants, and drugs abuse in brain regions 
such as the prefrontal cortex and the hippocampus 
(Palafox-Sanchez et al., 2019). 
NECTIN2 (nectin cell adhesion 
molecule 2) 
Location 19q13.32 
Starts at 44846136 and ends at 44878941 bp from 
pter.  
NECTIN2 is also called PVRL2 (poliovirus 
receptor-related 2). 
Protein 
NECTIN2 is a cell membrane protein involved in 
immune checkpoint, part of the TIGIT-PVR/PVRL2 
axis. NECTIN2 is composed of a signal peptide 
(amino acids 1-31), an extracellular domain (aa 32-
360), a transmembrane domain (aa 361-381), and a 
cytoplasmic domain (aa 382-538). NECTIN2 also 
interacts with PVRIG CD226, CD96 to stimulate or 
inhibit lymphocyte cell signaling (Stamm et al., 
2018; Whelan et al., 2019). 
PPP1R15A (protein phosphatase 1 
regulatory subunit 15A) 
Location 19q13.33 
Starts at 48872392 and ends at 48876062 bp from 
pter  
PPP1R15A is also called GADD34. 
Protein 
674 amino acids. PPP1R15A inhibits the 
proteasomal degradation of MCL1 and enhances 
MCL1 protein stability. PPP1R15A overexpression 
promotes MAPK signaling pathway through TRAF6 
and TAB1, which mediates the up-regulation of 
MCL1 (Song et al., 2019). 
SPIB (Spi-B transcription factor) 
Location 19q13.33 
Starts at 50418938 and ends at 50431052 bp from 
pter. 
Protein 
262 amino acids. SPIB contains two transactivation 
domains (aa 1-31 and 41-61). Binds to the nucleotide 
sequence GGAA. Transcriptional activator of B-cell 
development and differentiation. SPI1 (spleen focus 
forming virus (SFFV) proviral integration oncogene 
spi1, also known as PU.1) and SPIB control many 
components of the B-cell receptor (BCR) pathway. 
SPI1 and SPIB are partially redundant. Inactivation 
of SPI1 and SPIB in B-cell progenitors blocks the 
development at the pre-B-cell stage and induces pre-
B acute lymphoblastic leukemia. Inactivation SPI1 
and SPIB in mature B cells prevents germinal centers 
development. SPI1 and SPIB negatively regulate 
plasma cell differentiation (Willis et al., 2017). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
CEBPA and CEBPG cases: The breakpoints 
clustered within the 3' UTR of CEBPA in most cases, 
and was 31 kb centromeric of CEBPA in one case. 
The breakpoint was 52 kb centromeric of CEBPG 
(Akasaka et al., 2007). NECTIN2 case: The 
breakpoint in NECTIN2 was located in exon 1 in the 
5'untranslated region at position 45,349,458 from the 
p terminus of chromosome 19 (Otto et al., 2016). 
Fusion protein 
Oncogenesis 
In the case reported by Otto et al., 2016, NECTIN2 
was expressed at a significantly higher level than in 
the other 363 DLBCL studied. 
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